Timing is everything: new trial seeks best sequence of targeted therapy for breast cancer

NCT ID NCT07657130

Recruiting now Disease control Sponsor: Liaoning Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is recruiting 120 women with advanced HER2-negative breast cancer to find out whether it is better to receive antibody drug conjugates (ADCs) before chemotherapy or after. Participants will be randomly assigned to one of two sequences, and researchers will compare how long the cancer is controlled, overall survival, side effects, and quality of life. The goal is to optimize treatment timing for better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antibody drug conjugates (ADCs) such as trastuzumab deruxtecan or sacituzumab govitecan
What this could lead to: If successful, this trial could help doctors decide the best order to give ADC therapy and chemotherapy, potentially improving how long patients live without their cancer getting worse.
What could go wrong: This is a phase II trial with only 120 participants, so results are preliminary. The best timing may not clearly improve outcomes, and ADCs can cause side effects like nausea or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm female breast carcinoma Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER FEMALES

Contacts and locations

Locations

Liaoning Cancer Hospital & Institute
RECRUITING

Shenyang, Liaoning, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.